Credit Suisse AG Decreases Holdings in Arrowhead Pharmaceuticals, Inc. (ARWR)

Credit Suisse AG cut its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 41.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 61,803 shares of the biotechnology company’s stock after selling 44,181 shares during the period. Credit Suisse AG owned about 0.08% of Arrowhead Pharmaceuticals worth $115,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in Arrowhead Pharmaceuticals by 3.4% during the 1st quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock valued at $1,226,000 after buying an additional 21,654 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Arrowhead Pharmaceuticals by 3.7% during the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after buying an additional 11,099 shares during the last quarter. Wells Fargo & Company MN raised its stake in Arrowhead Pharmaceuticals by 144.8% during the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after buying an additional 88,933 shares during the last quarter. Teachers Advisors LLC raised its stake in Arrowhead Pharmaceuticals by 18.0% during the 4th quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock valued at $175,000 after buying an additional 17,201 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in Arrowhead Pharmaceuticals by 287.9% during the 1st quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 74,776 shares during the last quarter. Institutional investors and hedge funds own 20.63% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Credit Suisse AG Decreases Holdings in Arrowhead Pharmaceuticals, Inc. (ARWR)” was first reported by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.themarketsdaily.com/2017/09/11/credit-suisse-ag-decreases-holdings-in-arrowhead-pharmaceuticals-inc-arwr.html.

A number of brokerages have weighed in on ARWR. Jefferies Group LLC reiterated a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. Piper Jaffray Companies restated a “hold” rating and issued a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Finally, ValuEngine lowered Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company’s stock. Arrowhead Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $1.80.

Arrowhead Pharmaceuticals, Inc. (NASDAQ ARWR) traded up 9.3215% during midday trading on Monday, hitting $3.3999. The stock had a trading volume of 1,245,031 shares. The firm has a 50-day moving average of $2.20 and a 200 day moving average of $1.84. The firm’s market capitalization is $254.22 million. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $1.20 and a 52-week high of $8.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The firm had revenue of $9.34 million for the quarter, compared to analyst estimates of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. On average, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post ($0.42) EPS for the current year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply